VivoSeq
Oncology

Malignant Solid Tumor

18

Pipeline Programs↗

3

Active Trials↗

13

Companies Involved↗

Malignant Solid Tumor is an emerging landscape with 18 programs across 13 companies. The most active players are Merck & Co., Genmab, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc..

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

0/100

Mech. Concentration

18/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

2 programs

Phase 1Genmab logo

Genmab

1 program

Phase 1M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 1A

Avyxa

1 program

Phase 1Novartis logo

Novartis

4 programs

Phase 2Roche logo

Roche

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

14 of 15 classified programs — the dominant modality here.

7%ALL OTHERSMonoclonal antibody17%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 89% of 18 pipeline programs.

Analysis

Trial Status

5

clinical trials

Completed2 · 40%
Active, not recruiting2 · 40%
Recruiting1 · 20%

Clinical Trials

Trial Activity

Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor
Completed·JJenKem Technology Co., Ltd.·Phase 1·NCT04366648·25 enrolled
The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor
Completed·BeiGene logoBeiGene·Phase 1·NCT03641586·42 enrolled
MegaMOST - A Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /Characteristics in Advanced / Metastatic Tumors.
Recruiting·CCentre Leon Berard·Phase 2·NCT04116541·455 enrolled
A Phase 1 Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GEN1042 Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Japanese Subjects With Malignant Solid Tumors
Active, not recruiting·Genmab logoGenmab·Phase 1·NCT06057038·8 enrolled
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors
Active, not recruiting·Genmab logoGenmab·Preclinical·NCT04083599·350 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)